ANI Pharmaceuticals Inc. (NASDAQ:ANIP) was up 1.8% during trading on Tuesday . The stock traded as high as $61.44 and last traded at $57.00, with a volume of 785,652 shares trading hands. The stock had previously closed at $56.01.

Several equities research analysts have commented on ANIP shares. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 price target on the stock in a research note on Wednesday. Raymond James Financial Inc. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 price target on the stock. Citigroup Inc. lowered shares of ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 price target on the stock. in a research note on Friday, July 8th. They noted that the move was a valuation call. Standpoint Research lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 24th. Finally, Oppenheimer Holdings Inc. restated a “buy” rating and issued a $49.00 price target (up previously from $47.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, April 13th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $59.38.

The company has a market cap of $673.15 million and a price-to-earnings ratio of 55.05. The company’s 50-day moving average price is $55.20 and its 200-day moving average price is $42.84.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, May 5th. The specialty pharmaceutical company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.12. The company had revenue of $20.60 million for the quarter, compared to the consensus estimate of $21.03 million. During the same quarter in the previous year, the firm posted $0.57 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Equities research analysts expect that ANI Pharmaceuticals Inc. will post $3.63 EPS for the current fiscal year.

Other hedge funds have modified their holdings of the company. Deere & Co. acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at $1,961,000. Mutual of America Capital Management LLC raised its stake in shares of ANI Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 30,178 shares of the specialty pharmaceutical company’s stock valued at $1,362,000 after buying an additional 178 shares during the period. Finally, GSA Capital Partners LLP raised its stake in shares of ANI Pharmaceuticals by 10.8% in the fourth quarter. GSA Capital Partners LLP now owns 55,447 shares of the specialty pharmaceutical company’s stock valued at $2,502,000 after buying an additional 5,420 shares during the period.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.